Gas Prices

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Sensex @ 21,000?

Sensex @ 21,000?

Sensex to touch 21,000 by year end: Reuters poll.  Full Article 

Trade Reforms

Trade Reforms

U.S. groups form alliance to push for Indian trade reforms.  Full Article 

Financing Trouble

Financing Trouble

U.S. court lets stand Ex-Im Bank loan for Air India.  Full Article 

India in Depth

India in Depth

BREAKINGVIEWS - India in depth: Diaspora's yield hunt gone wrong  Full Article 

Revenue Milestone

Revenue Milestone

Exclusive - Facebook reaches 1 million active advertisers.  Full Article 

New Fed Chief?

New Fed Chief?

Obama says Bernanke has 'stayed a lot longer' than he wanted at Fed.  Full Article 

Reviving Infra

Reviving Infra

Road building revival offers rare hope for India infrastructure overhaul.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Pfizer considers purchase of India's Agila Specialties - report

Related Topics

Stocks

   
A view of the Belgian headquarters of U.S. pharmaceutical giant Pfizer, in Brussels January 23, 2007. REUTERS/Francois Lenoir/Files

A view of the Belgian headquarters of U.S. pharmaceutical giant Pfizer, in Brussels January 23, 2007.

Credit: Reuters/Francois Lenoir/Files

Tue Jan 15, 2013 2:10am IST

REUTERS - Pfizer Inc is considering buying India's Agila Specialties, the injectable-medicines unit of Indian drug supplier Strides Arcolab Ltd (STAR.NS), for a possible price of $2 billion, Bloomberg reported on Monday.

Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg reported, citing unnamed sources.

A Pfizer spokeswoman said the company does not comment on market rumours or speculation.

Agila makes cancer treatments and antibiotics, Bloomberg said.

Pfizer shares were up 23 cents at $26.75 on the New York Stock Exchange. (Reporting By Caroline Humer; editing by John Wallace)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.